Syros Pharmaceuticals Presents Data Demonstrating Significant …
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes.
Press Releases - Syros Pharmaceuticals, Inc. (SYRS)
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer Sep 7, 2022
Press Releases :: Syros Pharmaceuticals, Inc. (SYRS)
Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidates at 21st Congress of the European Hematology Association
SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 45-3772460 (I.R.S. …
Re: Syros Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-239141) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the …
Syros Pharmaceuticals, Inc.
We would like to show you a description here but the site won’t allow us.